EA202190748A1 - Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой - Google Patents

Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой

Info

Publication number
EA202190748A1
EA202190748A1 EA202190748A EA202190748A EA202190748A1 EA 202190748 A1 EA202190748 A1 EA 202190748A1 EA 202190748 A EA202190748 A EA 202190748A EA 202190748 A EA202190748 A EA 202190748A EA 202190748 A1 EA202190748 A1 EA 202190748A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
inhibitor
phosphoinositide
zinc
compound
Prior art date
Application number
EA202190748A
Other languages
English (en)
Inventor
Цзин ВАН
Трой Дэвид Паттерсон
Цзэ Тянь
Original Assignee
Кьюрис Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кьюрис Инк. filed Critical Кьюрис Инк.
Publication of EA202190748A1 publication Critical patent/EA202190748A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Согласно данному изобретению предложен способ лечения рака у субъекта, нуждающегося в этом, включающий введение данному субъекту (a) соединения формулы (I) или его фармацевтически приемлемой соли, где R представляет собой атом водорода или ацильную группу; и (b) ингибитора передачи сигнала, опосредуемой белком 1 программируемой клеточной смерти (PD-1); при этом соединение формулы (I) или его фармацевтически приемлемую соль и ингибитор PD-1-опосредуемой передачи сигнала вводят в количествах, которые в комбинации оказываются терапевтически эффективными. Согласно данному изобретению также предложена фармацевтическая композиция, содержащая соединение формулы (I) или его фармацевтически приемлемую соль, ингибитор PD-1-опосредуемой передачи сигнала и фармацевтически приемлемый носитель или эксципиент.
EA202190748A 2018-09-11 2019-09-10 Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой EA202190748A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729648P 2018-09-11 2018-09-11
PCT/US2019/050373 WO2020055840A1 (en) 2018-09-11 2019-09-10 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
EA202190748A1 true EA202190748A1 (ru) 2021-07-22

Family

ID=69721106

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190748A EA202190748A1 (ru) 2018-09-11 2019-09-10 Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой

Country Status (15)

Country Link
US (2) US11234986B2 (ru)
EP (1) EP3849554A4 (ru)
JP (1) JP7467423B2 (ru)
KR (1) KR20210087438A (ru)
CN (1) CN113164466A (ru)
AU (1) AU2019340376A1 (ru)
BR (1) BR112021004371A2 (ru)
CA (1) CA3112177A1 (ru)
EA (1) EA202190748A1 (ru)
IL (1) IL281303A (ru)
MA (1) MA53619A (ru)
MX (1) MX2021002742A (ru)
PH (1) PH12021550471A1 (ru)
SG (1) SG11202102343QA (ru)
WO (1) WO2020055840A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778212B (zh) * 2021-01-28 2022-03-15 苏州莱克施德药业有限公司 库潘尼西中间体2-胺基嘧啶-5-羧酸甲酯的合成方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2407593C (en) 2000-04-27 2011-01-11 Yamanouchi Pharmaceutical Co. Ltd. Fused heteroaryl derivatives
EP1485370B1 (en) 2002-03-13 2009-03-04 Janssen Pharmaceutica N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US7446109B2 (en) 2002-03-13 2008-11-04 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
NZ541772A (en) 2003-01-29 2009-10-30 Takeda Pharmaceutical Thienopyrimidine compounds and use thereof
EP1745022B1 (en) 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2522395A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
CN101374828B (zh) 2006-01-19 2012-09-19 詹森药业有限公司 作为组蛋白脱乙酰酶抑制剂的杂环烷基衍生物
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
RU2443706C2 (ru) 2006-04-26 2012-02-27 Дженентек, Инк. Фармацевтические соединения
WO2007127183A1 (en) 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US7781433B2 (en) 2006-04-26 2010-08-24 Piramed Limited Pharmaceutical compounds
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
JP2010502743A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス，インコーポレイテッド 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
KR101312993B1 (ko) 2006-10-28 2013-11-25 엔비보 파마슈티칼즈, 인코퍼레이티드 히스톤 데아세틸라아제의 억제제
TW200829594A (en) 2006-12-07 2008-07-16 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2007329352B2 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
KR20090110913A (ko) 2007-02-15 2009-10-23 노파르티스 아게 Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물
AU2007349284B2 (en) 2007-03-20 2012-10-04 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
CN101939006B (zh) 2007-09-12 2015-09-16 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
JP5452617B2 (ja) 2009-01-08 2014-03-26 キュリス，インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR101781654B1 (ko) 2009-03-12 2017-09-25 제넨테크, 인크. 조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물
WO2011054620A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
CN102970868A (zh) 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗
US8710219B2 (en) 2011-04-01 2014-04-29 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
PL3313443T3 (pl) * 2015-06-25 2023-11-06 Immunomedics, Inc. Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
CA3040033A1 (en) 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Substituted 1,2,4-oxadiazole compounds as dual inhibitors of vista and pd-1 pathways
WO2018085342A1 (en) 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Also Published As

Publication number Publication date
JP7467423B2 (ja) 2024-04-15
CN113164466A (zh) 2021-07-23
US20220249502A1 (en) 2022-08-11
WO2020055840A1 (en) 2020-03-19
PH12021550471A1 (en) 2021-11-22
MX2021002742A (es) 2021-08-11
EP3849554A4 (en) 2022-06-01
SG11202102343QA (en) 2021-04-29
US11234986B2 (en) 2022-02-01
BR112021004371A2 (pt) 2021-05-25
EP3849554A1 (en) 2021-07-21
IL281303A (en) 2021-04-29
KR20210087438A (ko) 2021-07-12
JP2022500374A (ja) 2022-01-04
US20200078364A1 (en) 2020-03-12
CA3112177A1 (en) 2020-03-19
MA53619A (fr) 2021-12-15
AU2019340376A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
EA202190630A1 (ru) Способы комбинированной терапии
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
BR112022012641A2 (pt) Compostos tricíclicos substituídos
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CR20230310A (es) Inhibidores de prmt5
EA201101507A1 (ru) Способы лечения солидных опухолей
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA202190749A1 (ru) Способы комбинированной терапии
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EA202190748A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA202190125A1 (ru) ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
MX2023001618A (es) Compuestos heterocíclicos como inhibidores de bcl-2.